Shares of Cardiff Oncology Inc. are trading higher. The company released new data on its lead clinical program evaluating onvansertib to treat certain colorectal cancer patients.
Cardiff Oncology said the program is evaluating onvansertib in combination with standard-of-care Folfiri/bevacizumab to treat certain colorectal cancer patients.
"Our Phase 1b/2 trial continues to generate data suggesting that the addition of onvansertib to SOC results in an objective response rate and median progression-free survival that substantially exceed those previously achieved with SOC alone," said Katherine L. Ruffner, chief medical officer.